Endocrine & hormone · target hub

SLC16A7

Monocarboxylate transporter 2 (SLC16A7)

SLC16A7 is a Hormone binding & transport on the endocrine & hormone axis. Proton-coupled monocarboxylate symporter. Catalyzes the rapid transport across the plasma membrane of monocarboxylates such as L-lactate, pyruvate and ketone bodies, acetoacetate, beta-hydroxybutyrate and acetate (PubMed:32415067, PubMed:9786900). Dimerization is functionally req… It is indexed under "Transporters for hormones & metabolites (selected)" on our pathway page for antibodies, inhibitors, and assay guidance.

Back to pathway overviewSearch: SLC16A7UniProt (O60669)

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of SLC16A7.
  • For nuclear receptors pair ligands, co-regulators, and reporter assays; for membrane receptors note GPCR/RTK downstream and desensitization.
  • Verify antibody clone, phospho-site, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Expression contextTissue/cell-type–dependent expression
Rare variantsSporadic variants—require functional validation
Pathway couplingCo-occurs with neighboring nodes on the hub

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for SLC16A7

  • Binding: SLC16A7 hormone SPR/radioligand binding.
  • Transport: membrane or nuclear transporter substrate uptake.
  • Binding globulins: free vs total hormone fractions.
  • Tissue distribution: liver/kidney expression & drug-interaction context.

SLC16A7 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for SLC16A7 studies (examples)

  • Tool lines: HepG2, HEK293T, MCF-7, HeLa, Caco-2—screen by SLC16A7 expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (SLC2A1, SLC2A2, SLC2A3, SLC2A4) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for SLC16A7 Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for SLC16A7 Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for SLC16A7 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-SLC16A7 for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous SLC16A7 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

SLC16A7SLC16A7 antibodySLC16A7 ligand/agonisthormone/receptor antibody

SLC16A7-related antibodies (keyword-biased)

Adds SLC16A7 keyword bias atop the 内分泌和激素 antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

SLC2A1SLC2A2SLC2A3SLC2A4SLC16A1SLC16A2SLC16A8SLCO1A2

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the endocrine & hormone hub for neighboring targets—cross-check PI3K, MAPK, RTK, and metabolism pages as needed.

Endocrine & hormone·PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Metabolism